Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: A randomized controlled trial

Archives of Internal Medicine

Volumn 172, Issue 12, 2012, Pages 922-928

  Carratalà, Jordi ^a   Garcia Vidal, Carolina ^a   Ortega, Lucía ^d   Fernández Sabé, Núria ^a   Clemente, Mercedes ^d   Albero, Ginesa ^e   López, Marta ^b   Castellsagué, Xavier ^e   Dorca, Jordi ^b   Verdaguer, Ricard ^c   Martínez Montauti, Joaquín ^d   Manresa, Frederic ^b   Gudiol, Francesc ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d Consorcio de Investigacion Biomedica en Red de Epidemiologia y Salud Publica ^*  (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COST CONTROL; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL PATHWAYS; EARLY AMBULATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PATIENT SATISFACTION; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84863004653     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.1690     Document Type: Article

References (33)

1. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Niederman MS. Community-acquired pneumonia: the US perspective. Semin Respir Crit Care Med. 2009;30(2):179-188.
3. European Respiratory Society/European Lung Foundation. Pneumonia. In: European Lung White Book. Sheffield, England: European Respiratory Society; 2003:55-65.
4. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med. 2000;109(5):378-385.
5. Bartolomé M, Almirall J, Morera J, et al; Maresme Community-Acquired Pneumonia Study Group (GEMPAC). A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J. 2004;23(4):610-616.
6. Carratalà J, Fernández-Sabé N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in lowrisk patients. Ann Intern Med. 2005;142(3):165-172.
7. McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med. 1999;107(1):5-12.
8. Garau J, Baquero F, Pérez-Trallero E, et al; NACER Group. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect. 2008;14(4):322-329.
9. Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J. 2006;13(6):317-324.
10. Garcia-Vidal C, Carratalà J, Díaz V, et al. Factors associated with prolonged hospital stay in community-acquired pneumonia. Enferm Infecc Microbiol Clin. 2009;27(3):160-164.
11. Ramírez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159(20):2449-2454.
12. Ramírez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161(6):848-850.
13. Oosterheert JJ, Bonten MJM, Schneider MME, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193.
14. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 2001;161(5):722-727.
15. Every NR, Hochman J, Becker R, Kopecky S, Cannon CP; Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association. Critical pathways: a review. Circulation. 2000;101(4):461-465.
16. Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med. 1995;123(12):941-948.
17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.
18. Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest. 2003;124(3):883-889.
19. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158(12):1350-1356.
20. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with communityacquired pneumonia. Arch Intern Med. 2004;164(5):502-508.
21. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG; CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000;283(6):749-755.
22. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med. 2003;115(5):343-351.
23. Stone RA, Mor MK, Lave JR, Hough LJ, Fine MJ. Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia. Am J Manag Care. 2005;11(8):491-499.
24. Halm EA, Horowitz C, Silver A, et al. Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care. Chest. 2004;126(1):100-107.
25. Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64(1):188-199.
26. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273-1276.
27. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111(5):367-374.
28. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279(18):1452-1457.
29. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278-1284.
30. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008;46(4):550-556.
31. Vergis EN, Yu VL. New directions for future studies of community-acquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis. 1999;18(12):847-851.
32. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-141.
33. Kozma CM, Dickson M, Raut MK, et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ. 2010;13(4):719-727.